Senate Leaders Rush to Strike New Bipartisan Drug-Pricing Deal

The leaders of two key Senate health committees are trying to strike a deal on a slate of drug-pricing bills, including ones to spur generic drug approvals, cut fees from pharmaceutical middlemen, and cap the cost of insulin.

The Democratic and Republican heads of the Finance and Health, Education, Labor and Pensions committees say they’re trying to mark up drug-pricing legislation in the coming weeks and assemble a package of bills that would also include some drug patent changes already approved by two other panels.

Having a long list of small policy changes that together could equal a major overhaul ...